Skip to main content
Markus Mapara, MD, Oncology, New York, NY, New York-Presbyterian Hospital

MarkusYMaparaMDPhD

Oncology New York, NY

Professor of Medicine, Director of Blood and Marrow Transplantation, Columbia University Medical Center, New York

Overview of Dr. Mapara

Dr. Markus Mapara is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from University of Heidelberg Faculty of Medicine and has been in practice 27 years. Dr. Mapara accepts several types of health insurance, listed below. He is one of 369 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He also speaks multiple languages, including German and French. He has more than 100 publications and over 500 citings.

Education & Training

  • University of Heidelberg Faculty of Medicine
    University of Heidelberg Faculty of MedicineClass of 1990

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2011 - 2025
  • PA State Medical License
    PA State Medical License 2005 - 2014
  • Internal MedicineHematology/Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Immunomodulatory Drugs Downregulate IKZF1 Leading to Expansion of Hematopoietic Progenitors with Concomitant Block of Megakaryocytic Maturation  
    Markus Y Mapara, Sara A Monaghan, Suzanne Lentzsch, Haematologica
  • Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin Lymphoma  
    Changchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology

Abstracts/Posters

  • Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: ...
    Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients
    Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations
    Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • A Gene Therapy Cure for Sickle Cell Is on the Horizon
    A Gene Therapy Cure for Sickle Cell Is on the HorizonMarch 15th, 2023
  • Boston University Reveals New Treatment for Sickle Cell Anemia
    Boston University Reveals New Treatment for Sickle Cell AnemiaApril 9th, 2022
  • Gene Therapy Trials for Sickle Cell Disease Hold Hope for Durable Effects
    Gene Therapy Trials for Sickle Cell Disease Hold Hope for Durable EffectsMarch 3rd, 2022
  • Join now to see all

Grant Support

  • Role Of STAT1 And STAT3 In Graft Versus Host Disease And Graft Versus Leukemia EFNational Heart, Lung, And Blood Institute2008–2011

Professional Memberships

Other Languages

  • German, French

Hospital Affiliations

Insurance Accepted

  • Empire BCBS PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment